Jagpreet Chhatwal
Jagpreet Chhatwal, MS, PhD, is the Director of the MGH Institute for Technology Assessment (ITA) and an Associate Professor at Harvard Medical School. His research is centered in decision science, data analytics, and health economics. He has co-authored over 100 research articles, and his work has been cited in leading media outlets, including NPR, Forbes, Wall Street Journal, and New York Times. Dr. Chhatwal’s work utilizes innovative methods to disseminate the findings of decision models to policymakers using interactive online platforms. He currently leads research in multiple disease areas, including hepatitis C, liver cancer, nonalcoholic fatty liver disease (NAFLD), opioid and alcohol use disorder, mental health, and COVID-19. He also teaches meditation workshops in different settings.
Interactive Online Modeling Tools:
- COVID-19 Simulator: The COVID-19 Simulator has a collection of tools to help health policymakers and practitioners make decisions regarding policy, and strategy related to coronavirus disease 2019.
- Hep C State Policy Simulator: Developed in collaboration with the CDC, the Hep C State Policy Simulator helps state health policy makers and practitioners make decisions regarding policy, strategy, and investments related to hepatitis C.
- Hep C Calculator: Developed in collaboration with the WHO, this interactive tool evaluates the cost-effectiveness of hepatitis C treatment and testing in different countries.
- NAFLD Simulator: The NAFLD Simulator is an interactive, open-access tool that provides information on the short- and long-term risks associated with with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis.
Selected News:
- Wall Street Journal: Your Office is Open and the Liquor is Flowing
- CNN: Your Office Is Open and the Liquor Is Flowing
- CNN: States Making up the SEC Have Low Vaccination Rates, but Stadiums Will Be at 100% Capacity as College Football Kicks off This Weekend
- Boston Globe: One Model Projects a Sobering Outlook for Rising COVID-19 Cases in the US and Mass. As Omicron Surges
- Boston Globe: Limiting Opioid Prescriptions Will Do Little to Reduce Overdose Deaths, Study Says
- Marketplace: Cutting Prison Hepatitis C Rates: Costly, But Worth It?
- Wall Street Journal: Hepatitis C Drugs Are Cost Effective, but Affordability Is Another Matter
- Forbes: Critical Reports Mount on Hepatitis C Pill Costs